Clinical Trials Directory

Trials / Unknown

UnknownNCT03863106

The Lyon Real World Evidence in Metastatic NeuroEndocrine Tumours

Status
Unknown
Phase
Study type
Observational
Enrollment
880 (estimated)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
All
Age
15 Years – 100 Years
Healthy volunteers
Not accepted

Summary

Neuroendocrine tumours (NETs) are rare and include a heterogeneous group of neoplasms derived from the endocrine system found in the gastrointestinal tract, pancreas and lung. Gastroenteropancreatic (GEP) NETs represent the majority of neuroendocrine neoplasms (NEN) and the annual incidence of all GEP-NETs has been estimated to 6.98 per 100,000 person-years in 2012 and is steadily rising. While data on the incidence of metastatic GEP-NET is limited, more than 50% of patients with GEP-NET have metastatic disease at the time of diagnosis. Incorrect and delayed diagnoses are still common. Treatment options include surgery, locoregional interventions, and systemic treatment. The Lyon Real world Evidence in Metastatic NeuroEndocrine Tumours study (LyREMeNET) is a descriptive observational cohort study. The main objective is to assess the healthcare resources use and the corresponding costs for management of patients with metastatic GEP and lung NETs. The secondary objective is to describe the clinical characteristics, prognostic factors, treatment patterns, and the overall survival among patients with metastatic GEP and lung NETs.

Conditions

Interventions

TypeNameDescription
OTHERMetastatic gastroenteropancreatic and lung neuroendocrine tumorsPatients with metastatic GEP and lung NETs will be selected via the Cancer Database on NEN of the Hospices Civils de Lyon. Data from this database will be matched with the French nationwide claims and hospitalization database (SNDS database), allowing access to the corresponding healthcare resources use and their related costs. Data regarding clinical and tumour characteristics and treatments patterns will be collected via the database between 1 January 1990 and 31 of December 2017.

Timeline

Start date
2017-07-15
Primary completion
2019-07-01
Completion
2020-07-01
First posted
2019-03-05
Last updated
2019-03-05

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03863106. Inclusion in this directory is not an endorsement.